Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

NCT04733508 · Unknown status

Last updated 2026-05-28

This clinical trial examines the presence of a specific protein (GLP1R) and the amount of insulin-producing cells in the pancreas of adults with type 2 diabetes using a special imaging scan.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) diagnostic study

Participants 28 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2019-11 · est. completion 2022-12

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT04733508 ↗

Description as written by the study sponsor.

Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes

Treatments tested

111In-DTPA-exendin-4 Drug

Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
IRDye800CW-exendin-4 Drug

Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy

Main thing measured	Pancreatic exendin uptake 111In-DTPA exendin-4
Sponsor	Radboud University Medical Center
Conditions studied	Diabetes Mellitus, Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04733508 ↗